AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00732069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
Study NCT03361241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Physiotherapeutic Intervention
Description: Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt.
Study NCT03361241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic Intervention
Description: Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
Study NCT04996420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearsight non invasive hemodynamic monitoring
Description: Goal directed fluid therapy fuided by Clearsight monitoring
Study NCT04996420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clearsight non invasive hemodynamic monitoring
Description: Goal directed fluid therapy fuided by Clearsight monitoring
Study NCT02923700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich PRP intra-articular injections
Study NCT02923700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor PRP intra-articular injections
Study NCT00314158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Description: One drop twice daily in each study eye for six months
Study NCT00314158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension
Description: One drop twice daily in each study eye for six months
Study NCT00314158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 5 mg/ml eye drops, solution
Description: One drop twice daily in each study eye for six months
Study NCT03686072 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract surgery with endoscopic goniosynechialysis
Description: Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
Study NCT03160716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Lyft with Lidocaine
Description: a sterile gel of hyaluronic acid (HA)
Study NCT00510614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: 1 gram twice weekly for 12 weeks
Study NCT00510614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one pill twice weekly for 12 weeks
Study NCT01645150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: 12 weeks of supervised progressive strength training
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V cefuroxime 750 mg*3/d for 2 days
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V ampicillin 2 gram x4/d for 2 days
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P.O cefuroxime 500 mgx2/d for 5 days
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P.O roxithromycin 150 mg*2/d for 7 days
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P.O roxithromycin 150 mg*2/d for 7 days
Study NCT02819570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P.O moxypen 500 mgx3/d for 5 days
Study NCT03606564 — intervention group
Intervention type: OTHER
Intervention: study of fasting time among pediatric patients undergoing day care surgery
Description: parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
Study NCT02329847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
Study NCT02329847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
Study NCT04940975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Insomnia Education Program at Integrated Mental Health Clinic (IMHC)
Description: A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
Study NCT01498887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720)
Description: Hard gelatin capsules containing 0.5 mg of fingolimod.
Study NCT01151852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
Study NCT01151852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
Study NCT01951352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap
Study NCT00616902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol injection 4 mcg/mL
Description: Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
Study NCT00616902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 4 mcg/mL
Description: Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
Study NCT02749344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FET after endometrial preparation
Description: Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
Study NCT03225287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
Study NCT02028598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration
Study NCT02028598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration
Study NCT02028598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses
Study NCT01562977 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
Description: until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
Study NCT04125979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In minimally invasive surgery，Vagus nerve preservation
Description: In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
Study NCT04125979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In minimally invasive surgery，Vagus nerve is not preserved
Description: In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
Study NCT00713804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
Study NCT00713804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Booklet
Description: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
Study NCT01414998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball vs Nicotine-free E-Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.
Study NCT01414998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Ball vs Nicotine-free E-Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.
Study NCT01414998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine-free E-Cigarette vs De-nicotinised Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.
Study NCT01414998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine-free E-Cigarette vs De-nicotinised Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.
Study NCT03044314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost and nitric oxide administration
Description: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
Study NCT02923765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training by a stepper
Description: Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
Study NCT00449163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00449163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Study NCT00449163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT00449163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT00606307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
Study NCT01690182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 1
Description: Volunteers will be fed with a high volume, high energy density test meal.
Study NCT01690182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 2
Description: Volunteers will be fed with a high volume, low energy density test meal
Study NCT01690182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 3
Description: Volunteers will be fed with a low volume, high energy density test meal
Study NCT03512522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Group
Description: An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
Study NCT03512522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workbook Group
Description: An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
Study NCT01102309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot therapy (NeReBot)
Description: Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
Study NCT01102309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
Study NCT01102309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
Study NCT03781726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir treatment
Description: combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
Study NCT04347408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody testing (IgG and IgM)
Description: Antibody testing for previous exposure to Covid-19
Study NCT04347408 — intervention group
Intervention type: OTHER
Intervention: Blood Storage
Description: Storage of blood for multi-omics analysis
Study NCT01107925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Administered orally, daily for 12 days
Study NCT01107925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Administered orally, daily for 12 days
Study NCT01107925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Administered orally, daily for 12 days
Study NCT00569452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump
Description: One basal rate
Study NCT00569452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump
Description: Multiple basal rates
Study NCT03765606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavanol beverage mix
Description: Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
Study NCT03765606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De-xanthinated Cocoa Flavanol beverage mix
Description: Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
Study NCT01677741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
Study NCT04241549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
Study NCT02807935 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical coherence tomography imaging
Study NCT04241549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
Study NCT02852460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid recovery
Study NCT03718429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg Tablet
Description: PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
Study NCT03641508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
Study NCT03641508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
Study NCT03279809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
Study NCT03279809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Case with placebo medication for 6 months after stenting
Study NCT03658551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein
Description: Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
Study NCT00545025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A
Description: Single dose, Intramuscular injection
Study NCT00545025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study NCT03883243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecoaching
Description: A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
Study NCT04301856 — intervention group
Intervention type: DRUG
Intervention: CFTR Modulators
Description: CFTR modulators as recommended in routine care by the french health authorities
Study NCT03908788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intplex test
Description: Blood sample at each tumor assessment
Study NCT02097823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT02097823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Study NCT01911416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT04354935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS basic
Description: 1 session per day, for 4 or 6 weeks.
Study NCT04354935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS VIIT
Description: 5 sessions per day, for 2 weeks.
Study NCT04354935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS SAINT modified
Description: 8 sessions per day, for 1 week.
Study NCT04354935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS SAINT
Description: 10 sessions per day, for 1 week.